Gastroenteropancreatic neuroendocrine tumors (GEP NETs) pose a significant treatment challenge due to their diverse biological behaviors and limited therapeutic options. The complexity of managing advanced GEP NETs is increased by the difficulty in establishing an optimal therapeutic sequence, as treatment decisions must consider tumor grade, differentiation, and somatostatin receptor (SSTR) expression while balancing efficacy with tolerability (1-3).
Cabozantinib: a promising advancement in the treatment of advanced neuroendocrine tumors / Panzuto, Francesco; Arrivi, Giulia; Marasco, Matteo; Rinzivillo, Maria. - In: AME CLINICAL TRIALS REVIEW. - ISSN 3005-6152. - (2025), pp. 1-4. [10.21037/actr-24-221]
Cabozantinib: a promising advancement in the treatment of advanced neuroendocrine tumors
Francesco Panzuto
Primo
;Giulia Arrivi;Matteo Marasco;Maria RinzivilloUltimo
2025
Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP NETs) pose a significant treatment challenge due to their diverse biological behaviors and limited therapeutic options. The complexity of managing advanced GEP NETs is increased by the difficulty in establishing an optimal therapeutic sequence, as treatment decisions must consider tumor grade, differentiation, and somatostatin receptor (SSTR) expression while balancing efficacy with tolerability (1-3).| File | Dimensione | Formato | |
|---|---|---|---|
|
Panzuto_Cabozantinib_2025.pdf
solo gestori archivio
Note: editorial
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
131.56 kB
Formato
Adobe PDF
|
131.56 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
